Merck’s (NYSE: MRK) Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023.
“We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, the successful launch of WINREVAIR and strong performance of our Animal Health business,” said Rob Davis, chairman and chief executive officer. “We’re continuing to progress our pipeline, advance key clinical programs and augment our pipeline through promising business development. Our business remains well positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential.”
Merck anticipates full-year 2025 worldwide sales to be between $64.1 billion and $65.6 billion.
Find more details on Q4 and full-year 2024 results below.
Our researchers incorporate LLMs to accelerate drug discovery and development
What are artificial intelligence (AI) agents? They're intelligent systems combining large language models (LLM), AI models and tools to iteratively plan, execute and optimize tasks
February 3, 2025
Share this article
Did you know that LLMs can be leveraged as master multitaskers? These LLM-based multitaskers, often called AI agents, can execute different tasks simultaneously. Having a team of high-performing AI assistants that can each play different roles ultimately helps researchers at Merck Research Labs (MRL) focus on critical drug discovery and development.
In today’s data-driven world, AI agents are emerging as a powerful tool for researchers and scientists to aid them in navigating the complexities of large data sets, refining hypotheses and executing both repetitive and differentiated tasks efficiently. Done manually, that kind of data gathering and analysis costs time and money.
Merck researchers use AI to augment human ability
A long-standing ambition for AI is to help find major scientific discoveries, learn on its own and acquire knowledge autonomously. This is what some call an “AI scientist.” While this concept is aspirational, advances in agent-based AI can help pave the way for the development of AI agents as conversable systems capable of reflective learning and reasoning that coordinate LLMs, machine learning (ML) tools, or even combinations of them.
Rather than taking humans out of the discovery process, AI can augment human ability to break down a problem into manageable subtasks, which can then be addressed by AI agents with specialized functions for targeted problem solving and integration of scientific knowledge. One significant advantage of these collaborative systems is their capacity for automation. Repetitive tasks, such as data cleaning or preliminary analysis, can be handled by AI agents, freeing our scientists to focus on higher level work and strategic decision making.
“We’ve already deployed AI agents, including in development workflows like medical writing, where agents query and assemble knowledge, and evaluate both human and AI writing.”
Matt Studney Vice president, information technology, MRL
“We see broad applicability of AI agents, for example in orchestrating discovery workflows, where agents can help researchers in generating molecular design ideas and insights, optimize assay workflows and generate biology insights integrated across cells, organisms and human genomics,” he said. “We see agents making the R&D process faster and crucially driving higher quality results. Agents help capitalize on Merck’s long-standing investments in AI/ML by rapidly accelerating the speed of our human researchers at scale.”
Advance your data science career with us
We’re looking for scientists and technologists who are passionate about making a difference for patients.
Find out why it's important to follow cancer screening recommendations
January 15, 2025
Share this article
youtube
https://www.youtube.com/watch?v=wxQ2vVvjKME
:
We’ve all had the feeling that there aren’t enough hours in the day. In between everything else on the to-do list, it can feel hard to make your health and annual appointments a priority. However, it’s important to take control of your health and talk to your doctor about what cancer screenings might be recommended for you.
Why timing matters in cancer screening
Time is important with a cancer diagnosis so that treatment can be started early, before cancer has spread to other parts of the body. Cancer screenings can increase the chance of finding disease before a person has symptoms or when cancer is still in earlier stages.
There are screening guidelines for many types of cancer, such as breast, colorectal and lung cancer, as well as melanoma. Screening recommendations often take into consideration a few factors, such as age, family history and lifestyle. Your doctor can help you identify which screenings might be right for you.
As a leader in oncology, we’re committed to addressing the global impact of cancer.
“Through our work to increase access to screening and our other initiatives and programs, we appreciate the importance of finding disease early, before it has spread to help enable early treatment, because we believe people with cancer deserve more,” said Linda Kollmar, associate vice president, medical affairs, value and implementation.
So, make time now to talk to your doctor and to find out if you’re eligible for cancer screening.
We’re working to help address other barriers to cancer screening
Raising awareness about cancer screening is just one way our company works to help improve lives. We also strive to help address barriers to screening and treatment, which is why we work with partners around the globe to support public health initiatives that support recommended screening and create access to high quality cancer care for all patients.
Our support of the American Cancer Society’s Get Screened initiative makes it possible for community members to be screened for breast, cervical, colorectal and lung cancer who might not have access otherwise. And working with City Cancer Challenge, we support the Patient Navigation Program in Kigali, Rwanda to train nurses as patient navigators who can help people understand health information more easily and gain access to health care options more quickly.
Honoring a life and legacy of profound impact for global health
December 29, 2024
Share this article
Former President Jimmy Carter exemplified a life of service, first through his governorship and presidency, and later through the Carter Center and its commitment to improving the health and well-being of those most in need. We are privileged to have worked side-by-side with President Carter and the Carter Center on its ongoing work to eliminate river blindness in countries throughout Africa and Latin America.
Over decades of our partnership through the Mectizan® Donation Program, the Carter Center has distributed more than 500 million treatments in our shared efforts to donate Mectizan — as much as needed, for as long as needed.
While President Carter did not want to take credit for the program, all of us at Merck know it was his leadership and commitment to global health that made this a reality.
We share in the grief of all those whose lives have been touched by President Carter. They are a living testament to his compassion, selflessness and generosity.
President Carter’s memory will guide and inspire us as we continue our work for patients and communities.
May he rest in the peace he wished for the world.
Pictured above: Jimmy Carter and retired Merck CEO Dr. Roy Vagelos meet with people affected by river blindness, 1994.
Podcast: How AI can improve insight into disease biology
A scientist explains how we’re using AI capabilities to help identify patterns in tissue and tumor samples indiscernible to the human eye
December 18, 2024
Share this article
We see the potential of data science, artificial intelligence (AI) and machine learning (ML) to help investigate new areas, pathways and mechanisms that may forge new opportunities to strengthen our pipeline through enhanced insights.
In a recent episode of the Health Pulse podcast by SAS, Dr. Greg Goldmacher, associate vice president, clinical research, and head of clinical imaging and pathology at Merck, discussed how we’re using these AI capabilities, like computer vision, to improve disease biology insights and help with objective imaging analysis to identify patterns indiscernible to the human eye.
“If you have AI tools that are trained to pick up subtle early signs of disease on scans that are being done for other reasons, there’s a real opportunity there for earlier diagnosis,” said Goldmacher in the podcast episode. “If you’re going to do opportunistic screening, for example, and want to train AI for that, what you need is longitudinal data sets where you can find patients who had the disease, and then go and look for scans that they might have had in the past to use to train the disease-recognizing models.”
Building on our understanding of gynecologic cancers
How we’re driving research forward for women with common types of gynecologic cancer
December 16, 2024
Share this article
By the numbers, the impact of gynecologic cancers feels overwhelming. The term “gynecologic cancers” primarily refers to cancers of three organs: the uterus, ovaries and cervix. As of 2022, these gynecologic cancers are some of the most commonly occurring cancer types for women worldwide. Even with advances in prevention and treatment, nearly 700,000 are projected to die from these diseases every year.
“To truly understand where we can begin to make progress, we need to look beyond the numbers,” said Dr. Gursel Aktan, vice president, global clinical development.
Understanding the trend
While “gynecologic cancers” primarily refers to the three cancer types mentioned above, it may also include cancers of the fallopian tube, vagina, and vulva.
“While the gynecologic cancer rates vary from country to country, the overall incidence rates of endometrial and cervical cancers have increased over time.”
Dr. Gursel Aktan
Endometrial cancer, which affects the lining of the uterus, is the most common gynecologic cancer in developed countries. Incidence rates for cervical and endometrial cancers, which mainly affect post-menopausal women, have been rising globally over the last two decades. The highest rates of diagnosis and death from gynecologic cancers were found in Eastern and Southern Africa and Melanesia.
“Unfortunately, many women may not recognize their symptoms as abnormal until their tumors are larger or may have spread,” said Dr. Aktan.
Building on what we have learned
“As our understanding of cancer continues to improve, there have been meaningful advances in cancer therapy, but we still have work to do to achieve our goal of helping more patients,” said Dr. Aktan.
To build on that momentum, we’re driving forward research focused on novel approaches for patients with certain gynecologic cancers with ~12 clinical trials for ~8,000 patients around the world. This work is grounded in our company’s three key focus areas in oncology research:
Evaluating combinations that play different roles in adjusting the immune response.
Precision molecular targeting to impact pathways that drive cancer growth.
Investigating ways to increase cancer cell sensitivity to immune responses.
“We’re also still learning about the right sequence in which to use treatments, and the truth is, the answers may be different tumor by tumor, patient by patient,” said Dr. Aktan.
“The better we understand how we can use these approaches to further cancer care, the closer we move toward our ultimate goal of supporting patients touched by cancer.”
Many people struggle to understand health information, which can impact health outcomes. What we're doing to support health literacy.
December 6, 2024
Share this article
What is health literacy?
At points in our lives, we need to make health or medical decisions for ourselves, members of our family or those in our care. And sometimes it can be challenging. Whether it’s deciding to receive a vaccine, start a new medication, undergo a procedure or join a clinical trial, our level of health literacy — the ability to find, understand and use information and services — can play an important role in health outcomes. Unfortunately, when people struggle, there may be negative health consequences, like decreased adherence to treatment plans, increased emergency room visits and hospital stays, and higher mortality rates.
Low health literacy is more common in vulnerable populations
While limited health literacy can affect anyone, there are certain populations at greater risk: older adults, racial and ethnic minorities, those with low income or less education, and people with compromised health status.
“As a company committed to helping save and improve lives, it’s our responsibility to communicate in a way that people can understand so that they can make informed health decisions,” said Shehla Hussain, director, medical writing safety services.
Health literacy is important for health equity
People with better health literacy are more likely to proactively engage in disease preventive behaviors and make informed decisions about their well-being. On the other hand, people with lower or limited health literacy may struggle to understand relevant information, leading to an increased risk of poor health outcomes.
How we’re making medical information easier to understand
We’re committed to making sure the information we share with the world is very clear. It’s something we’ve focused on since 2011, long before the U.S. Department of Health and Human Services updated the definition of health literacy in 2020 to acknowledge that organizations have a responsibility to equitably enable individuals to find, understand, and use information and services to inform health-related decisions and actions for themselves and others.
As part of our efforts, we created a plain language glossary and established company-wide standards focused on improving the health literacy of the information in our resources and materials. It starts in product development and continues through the life cycle of the product, including clinical trials, labeling, post-approval, marketing and promotional materials. For example, we’re:
Expanding our plain language glossary of medical/scientific terms
Supporting research on health literacy.
Utilizing plain language and graphics in digital and online resources.
Sharing best practices externally.
We also listen to the people who use or may use our products to help guide our efforts.
“We work to build trust by listening to the communities we serve, understanding their needs and making our information clear, concise and understandable.”
– English D. Willis
Executive director, clinical safety and risk management, and executive sponsor, Health Literacy Community of Practice
Reducing health disparities around clinical trials
“Health literacy is critically important for achieving clinical trial diversity as it ensures that individuals from diverse backgrounds can understand trial information, make informed decisions and effectively participate. Improving health literacy is essential for equitable access and participation, fostering greater inclusivity in research, leading to more representative and impactful outcomes” said Luther Clark, executive director, medical affairs, patient innovation and engagement.
Euvon Jones, a clinical trial participant, said: “Knowledge is power, and during my journey with prostate cancer, I realized the importance of fully understanding my diagnosis and the options available to me. Through conversations with my doctor and loved ones, and seeking information from reliable sources, I felt empowered to make informed decisions. When we fully understand the importance of the health information we receive, we’re better equipped to navigate the health care system, communicate with providers and advocate for the best possible care.”
Look at some examples of our work
Defining complex medical terms in plain language
By defining common terms used by health care providers, patients feel more prepared and confident to engage in discussions with their care teams.
Easy to navigate website
Understanding the patient's perspective allowed us to create a website that anticipates their needs for easy navigation. Plainer language, effective visuals and simple layouts make the website a useful tool.
Seeing from the patient perspective
In a diabetes awareness brochure, we presented the view from the patient's perspective so they can see the potential effects of eye damage from diabetes.
“And our work isn’t done. While we continue to learn and engage with communities, we’re also learning better ways to communicate with our consumers, patients and the general public.”
In the U.S., approximately 38.4 million people are living with diabetes, of which 90-95% is type 2 diabetes. And, while diabetes is a major health concern, there are common misconceptions around type 2 diabetes diagnosis and management that should be addressed.
What is type 2 diabetes?
Type 2 diabetes is characterized by resistance to insulin, a hormone produced by the pancreas, which helps glucose get into the body’s cells to be used for energy. In people with type 2 diabetes, the body isn’t able to properly use insulin, which allows too much glucose to build up in the blood and causes high blood sugar.
Here are some type 2 diabetes misconceptions explained.
01.
Misconception: Type 2 diabetes is not a serious disease.
Explanation: Type 2 diabetes should be taken seriously. If type 2 diabetes is not managed properly, it may lead to serious complications over time. Diabetes management, including learning about the condition, adopting a healthy lifestyle and working with a health care provider to create a treatment plan, can help decrease the risk of long-term complications.
02.
Misconception: If you have type 2 diabetes, the symptoms are obvious.
Explanation: Type 2 diabetes symptoms may develop slowly, often over several years, and can be so mild that it’s easy for symptoms to go unnoticed. Many people have no diabetes symptoms at all. In fact, approximately 23% of U.S. adults with diabetes are undiagnosed.
Type 2 diabetes symptoms may include:
Excessive thirst and/or hunger
Frequent urination
Blurred vision
Numbness or tingling in the hands and/or feet
Fatigue
Cuts and bruises that are slow to heal
03.
Misconception: All people with type 2 diabetes are overweight.
Explanation: While research shows that people who are overweight and who are not physically active are more likely to develop type 2 diabetes, there are other personal and lifestyle factors that can increase a person’s risk of developing the condition, including:
Age (45 years or older)
First degree family history (mother, father, sister, brother)
Ethnicity (African Americans, Hispanic/Latinx Americans, American Indians, Alaska Natives and some Pacific Islanders and Asian Americans are at higher risk)
04.
Misconception: If a family member has type 2 diabetes, you’ll also develop type 2 diabetes.
Explanation: If your mother, father, sister or brother has type 2 diabetes, you may have an increased risk for developing type 2 diabetes. However, this is only one of several risk factors. Adopting healthy lifestyle habits may help reduce your risk.
05.
Misconception: Type 2 diabetes only affects blood sugar.
Explanation: People with type 2 diabetes are twice as likely to have heart disease or a stroke. However, there are steps that can be taken to help reduce the risk of some of the more serious complications. These include keeping blood sugar levels as close as possible to a person’s individualized goal, eating healthy foods, exercising regularly, and maintaining blood pressure and cholesterol at levels set by a health care professional.
06.
Misconception: Type 2 diabetes can be cured.
Explanation:There’s no cure for type 2 diabetes as for many, it’s a progressive disease. However, there are some lifestyle changes that can help manage the condition, including making healthy food choices and increasing physical activity. Choose whole, minimally processed foods, such as fruits, non-starchy vegetables, whole grains, lean proteins and low-fat or skim milk cheese, as well as water over juice. Pay attention to how much you are eating, as larger portion sizes mean more calories. Additionally, exercise has been shown to improve blood glucose control, reduce cardiovascular risk factors and contribute to weight loss. Lifestyle changes alone may not be enough to control blood sugar. That’s why it’s important to work with your health care provider to develop an individualized treatment plan.
Merck’s (NYSE: MRK) Q3 2024 financial results represent strong progress across the business and our diverse pipeline. Our company announced worldwide sales of $16.7 billion, an increase of 4% from Q3 2023.
“Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond,” said Rob Davis, chairman and chief executive officer. “Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a more diversified portfolio to drive growth. I continue to remain confident in the strength of our business and our ability to execute, and I want to thank our colleagues across the globe for their focus and commitment as we work to create lasting value for patients, shareholders and all our stakeholders.”
Merck anticipates full-year 2024 worldwide sales to be between $63.6 billion and $64.1 billion.
Learn more about invasive pneumococcal disease and how infection spreads
Invasive pneumococcal disease can lead to a number of serious consequences in children
October 25, 2024
Share this article
What is invasive pneumococcal disease?
Invasive pneumococcal disease (IPD) is an infection caused by a bacteria called Streptococcus pneumoniae. It can lead to a number of serious illnesses including pneumococcal bacteremia (an infection of the blood) and pneumococcal meningitis (an infection of the coverings of the brain and spinal cord).
Children under the age of 2 and those with certain underlying medical conditions are particularly vulnerable to invasive pneumococcal disease, according to the Centers for Disease Control and Prevention (CDC).
~100
different types of S. pneumoniae, called serotypes, exist; however, a smaller number are responsible for most cases of IPD in children
~1 in 4
cases of IPD in children under 5 years of age were caused by serotypes 3, 22F and 33F, according to a pooled analysis from 2018-2021
How does pneumococcal infection spread?
Pneumococcal bacteria can spread anywhere, anytime through close contact with respiratory secretions, like those produced from coughing or sneezing. Children can carry the bacteria in their nose or throat without demonstrating signs of illness.
Pneumococcal infections are more common during winter and early spring when respiratory diseases are more prevalent.
What you can ask your pediatrician about pneumococcal infection:
Is my child at risk for invasive pneumococcal disease?
How could invasive pneumococcal disease harm my child?
What can I do to help reduce the risk of invasive pneumococcal disease for my child?
“There are steps people can take to be proactive about their family’s health. Parents should speak with their health care providers to learn more about invasive pneumococcal disease and the serious consequences it can cause.”
Dr. Ulrike Buchwald, scientific associate vice president, clinical research
Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.